Under the Clinical Laboratory Improvement Act of 1967 the Health Care Financing Administration's proficiencytesting requirement applies to -12 000 hospital, reference, and large-clinic laboratories in the United States. The Wisconsin State Laboratory of Hygiene is approved by the Health Care Financing Administration to provide proficiency testing in all specialties and subspeclaltles. The focus of the program is to provide highly specialized service and support to a limited number of participants in order to assess intralaboratory performance correctly.We report the findings over the four proficiency-testing events in 1991 for the subspeciafty of routine chemistry, which serves -470 participants. Failure rates for indMdual analytes on single proficiency testing events ranged from 0% to 13%. After four events or one year, if the mandated evaluation criteria and failure rules were strictly applied, as many as 11% of the laboratories could have found themselves involuntarily suspended from offering all routine chemistry testing.
When the Health Care Financing Administration (HCFA) introduced the revised regulations for the Clinical Laboratory Improvement Act (CLIA) of 1967 on March 14, 1990, regulatory proficiency testing (Fl became the fundamental means for assessing laboratory performance in the United States (1). The PT format was revised from the customary format of two samples four times per year to a format of five samples four times per year (2, 3) . In addition, the criteria for "satisfactory" or "passing" performance were revised significantly. Table 1 summarizes the HCFA performance criteria for each analyte. HCFA requires that PT providers apply for certification to that agency and agree to use the specified criteria as minimum performance-assessment standards. In 1991, there were 14 approved PT providers, but only 4 offered the full range of PT specified in the CLIA regulations, thus encompassing all laboratory specialties and subspecialties.
Included among the four is the Wisconsin State Laboratory of Hygiene (WSLH).
The source of the data for the current study is the WSLH Routine Clinical Chemistry Proficiency Testing Program, which provides this service for -470 participants in the subspecialty. ' The WSLH PT program, by design, is focused on laboratories in the state of Wisconsin, but it can and does accommodate a limited number of additional participants. In contrast to programs provided by the College of American Pathologists (CAP) and the American Association of Bioanalysts, which have nationwide constituencies and are designed to be much larger, the focus of the WSLH program is to provide highly individualized service to relatively few participants.
We aggressively seek to interpret and apply the mandatory CLLA/ HCFA regulations and grading criteria governing PT, to optimize the efficacy of the PT exercise and correctly assess laboratory performance.
This often means use of peer-group grading, as opposed to "grand means" and reference-method values to overcome specimen-induced bias problems. A second major objective of our program is to demonstrate that the reliance on PT as a measure of laboratory performance, using HCFA's mandated PT format, can be practicable-i.e., that it will grade laboratories fairly, consistently passing laboratories with acceptable performance and reliably detecting those having inferior performance. We also wish to demonstrate that a program run under these conditions can consistently meet the 45-day turnaround time requirement. By virtue of WSLH's approach to implementation of mandatory PT under these optimum conditions, which amounts to a (relatively) controlled experiment, we hope to confirm the utility of PT as a measure of laboratory performance. We are consciously seeking to evaluate the utility of PT as a means of correctly assessing laboratory performance, and we may have an opportunity to suggest improvements or modifications in the long-term use of PT progrpmming, mpking it a more effective and useful laboratory quality-assurance tool.
In the opinion of many laboratorians, PT, as envisioned under CLIA, becomes primarily a regulatory exercise. The strict HCFA requirements (1), along with the detailed prohibitions and penalties for "cheating," have the effect of minimizing the educational and quality-assurance aspects of this exercise (4, 5) . This must be viewed as an unfortunate loss of an important qualitymanagement opportunity and the imposition of a rather foreboding regulatory exercise on already overburdened laboratory personnel. The reaction of laboratory personnel can, at worst, be viewed as cheating (6) or, at best, as addressing the need to "pass" by achieving acceptable results, rather than quality results, through adopting various strategies (7) . If the grading group does not meet the required 80% agreement, all results in that group are deemed satisfactory. Also, if it is determined that a problem (i.e., matrix effect) exists for a particular PT specimen, then all results for that unknown are deemed satisfactory.
Results from each laboratory were assessed to determine violations of the 80% correct responses across all analytes tested and (or) the 4 of 5 correct within each analyte rules. Reports were returned consistently to participants within the specified 45-day limit, showing their final grades and their status with respect to HCFA criteria. During 1991, all PT results were graded, even though HCFA announced in May that results from Event 1 (i.e., the first quarter's samples) would not initiate any "adverse actions" to be taken against laboratories failing PT. In October 1991, HCFA announced that no PT data for 1991 would be used as the basis for adverse actions. Although the grades for 1991 therefore "didn't count," it is reasonable to look at the performance of laboratories, using the grades as a means of assessing the viability of HCFA's regulatory process, and to explore possible limitations of PT as specified by CLIA '67.
Results Table 2 details the performance of laboratories evaluated by the 80% correct across all analytes tested rule over the four PT events of 1991. As is immediately obvious, the percentage of laboratories passing this rule is impressively large. Note that the 80% across all analytes rule is relatively easy top for large laboratories, which typically use multi-channel or multi-analyte analyzers. Satisfactory performance on four analytes actually compensates for zero performance on the fifth analyte (20 of 25 correct = 80%)! But this rule tends to be more of a problem for a laboratory measuring only two, three, or relatively few analytes. The average number of different analytes reported by laboratories in the WSLH (Westlake, OH). These commercial controls exhibit the well-known limitations associated with the use of nonfresh human specimens, including vial-to-vial variation, turbidity, time-dependent reconstitution, and nonhuman sources of analytes. These limitations often are referred to collectively as "matrix effects."
Five samples were mailed to participants on a quarterly basis, beginning in January 1991. All data (five results for each analyte) are entered into a database by analyte. The data are then divided into instrumentspecific groups by code numbers. An instrument-specific group consists of 10 or more results with the same code. Statistics [ the "average" laboratory would report 60 individual results and would need to have 48 of 60 correct if it is to pass this rule. We do not consider the 80% correct across all analytes rule of major value in assessing laboratory performance, though some laboratories actually failed this rule on two consecutive events.
In Table 3 , we detail, by analyte, the percentage of laboratories passing the 4 of 5 correct within analyte rule. For each event, we list the number of laboratories participating and the percentage of laboratories passing the criterion for each analyte. In general, >95% of laboratories achieved at least four out of five correct results for each analyte analyzed. Table 4 indicates the number and percentage of laboratories that would experience an adverse action, which would result from failing the same analyte in two of three consecutive PT events under HCFA's rule of March 14, 1990. As specified in HCFA's rule, an adverse action can result in an order to cease testing in the entire subspecialty of routine clinical chemistry. For example, failing to meet the criterion for a single analyte, such as triglycerides, theoretically placed the laboratory in jeopardy of an HCFA order to cease measuring triglycerides as well as any other analytes in the subspecialty of routine clinical chemistry. After the initial publication of that rule, HCFA has indicated informally that a laboratory facing an adverse action because of a particular analyte failure may "voluntarily" suspend testing for that analyte only and, therefore, maintain the other analytes in the specialty or subspecialty in active status. Suspension of even one analyte is a particularly onerous burden on laboratories, because reinstatement requires successful performance in at least three events, one of which must be monitored on site. In effect, this suspension could last a minimum of six to seven months and probably nine or more, under even the most optimistic scenario of voluntarily suspended operation. Although these regulations remain in force until the CLIA '88 rule is implemented (probably late 1992 or early 1993), HCFA has indicated that it might pursue a less severe course. This is outlined in the April 2, 1991, Federal Register (8) . Of course, the decisio#{241} not to grade or enforce adverse actions renders this argument powerless, at least for 1991! Nevertheless, laboratorians are concerned that local inspectors may choose to enforce the existing CLIA regulations literally. There are no provisions for an appeal of the decision or for a reprieve while the matter is being petitioned. Table 5 summarizes the frequency, by analyte, of PT violations, which could have resulted in an adverse action over 1991's four PT events. To be subject to an adverse action, a laboratory must fail the 4 of 5 correct rule for a particular analyte (i.e., have two or more incorrect results) in two of three consecutive PT events. For example, a laboratory would be subject to adverse action by failing to meet the criteria for triglycerides in events one and two, one and three, or two and three. In columns 2 through 6 we indicate, by analyte, the percentage of laboratories participating that are potentially subject to suspension.
Discussion
Over the first four PT events under revised CLIA '67, we have seen what appears to be consistently good performance as reflected by the very high percentage (95+) of laboratories passing the 80% across all analytes rule. The high percentage of laboratories successfully passing the 4 of 5 correct within analyte rule is also excellent, with the possible exception of measurements of chloride, glucose, and sodium, though overall rates exceed 90%.
At this point we must draw the fundamental distinction between a voluntary quality-assurance PT program and a regulatory program. Whereas it might be acceptable to inform 1 out of 20 participants that it may be The failures could not be attributed to any one particular system, instrument, or reagent. In almost every case,alaboratoryfailingananalyteisinagroupof laboratories using similar instruments, all others of which are performing within HCFA guidelines. This strongly implies that the failure is due to individual calibration problems, which manifest as PT bias as described elsewhere (9). We could not identifr any TRIG peer laboratories, using identical systems, were successful in their analyses of the same specimens strongly implies that the problem is internal rather than attribprudent to focus quality-control activities on a particuutable to the PT process as conducted by the WSLH. We lar test, it is quite another to place that same percentage think this is in large part a result of the fundamental of laboratories in a position where the whim of some operating philosophy of the WSLH program. In the federal or state bureaucrat could result in a "shutdown" WSLH program we vigorously attempt to create approorder with no mechanism for appeal. Some have sugpriate instrumentlmethod grading groups and thus gested a court-imposed restraining order as an apavoid the issue of idiosyncratic bias caused by the preach. However, even when the minimum consequence intractable combination of methods designed for fresh is an impoundment of all (not just laboratory related) human-serum specimens and the nature of the PT Medicare/Medicaid payments, the pressure to perform materials. By careful grouping of these like methods, becomes intense. Federal rules notwithstanding, there the target value, which is the mean of a group of is probably no laboratory director, chief, or bench techparticipants, becomes a highly specific mean for a parnologist who is pleased by failing in any activity that ticular group of instruments. As a result, bias intropurports to measure quality.
duced as a result of matrix effects in the PT materials Given the profound effect on laboratories, we should affects each instrumentlreagent system equally and, ask if the HCFA-mandated grading criteria for these therefore, tends to be canceled out. In the absence of analytes are too stringent. It is most instructive to look highly specific methodology groupings, method-toat the last three events, where we observe a total of 45 method differences, which manifest themselves on PT two of three consecutive event failures for an analyte specimens but not necessarily on fresh samples from outofapopulationconsjstingof-5500possibleanalyte/ humRn patients, are responsible for most of the PT laboratory/event combinations. the size of the operation lends itself to achieving the short turnaround times mandated in the CLIA rules, i.e., 45 days. Even for our program, this represents quite a challenge. We feel, however, that the major strength of the program lies in our ability to respond to individual laboratories' concerns and questions. Each of the laboratories finding itself in failure status was personally contacted by WSLH with an offer of assistance. In many cases, through telephone consultation, we were able to discover sources of problems and suggest methods of correction. However, the program operators (B.J.L., B.J.B.), the persons most intimately familiar with the data, find that a very substantial proportion of the failing laboratories are doing so for logistical/mechanical reasons rather than because of poor technical performance. These errors include inaccurate reconstitution, disordered samples, transposition of numbers, incorrect decimal-point placement on the reporting sheets, and failure to return results by the date due (Table 6 ). Each of these errors generates, by HCFA criteria, a zero score for the result or shipment.
The WSLH program has set out vigorously to establish use of relevant peer groups for grading purposes when necessary. Some would argue that this seriously compromises the use of PT to assess accuracy and validate methods. In the worst case this could even perpetuate the existence of biased methods. Undoubtedly these are valid concerns. Because regulatory PT raises the specter of adverse consequences for failure to achieve satisfactory performance (consequences ranging from increased costs to pursue and document PT failure through possible HCFA shutdown orders), the PT provider has the responsibility to eliminate invalid assessments of performance. Until the matrix problems can be overcome with better quality specimens, we see no alternative.
Actual cholesterol performance data, from a reputable laboratory in Wisconsin, support this position. Clearly, to fail this laboratory for cholesterol PT represents a failure of the PT process, not the laboratory. To suggest that a calibration change is in order would be to serve poorly those patients and physicians who are using National Cholesterol Education Program guidelines. It makes no sense for this laboratory to risk a shutdown order or to voluntarily withdraw from testing cholesterol. The solution, as we see it within the existing HCFA rule, has two approaches: (a) switch to use of frozen human-serum specimens (as in New York State), or (b) use aggressive and highly individualized grading systems to overcome the limitations of the PT specimens. The former is not practicable on a large, national scale; the latter is the Wisconsin approach.
We conclude, as apparently HCFA has, that PT is the only practical solution to meeting the regulatory requirements imposed on all U.S. laboratories by Congress under CLIA '88 (11). CLIA '67, March 14, 1990, has long been recognized as a prelude to CLIA '88. Even with the most "enlightened" enforcement of the HCFA rule, coupled with individual consultation, prompt turnaround, and a "small but friendly" approach, HCFA's PT will result in unacceptably high failure rates among good laboratories. We think that a 5% rate is too high. The only practical solution appears to be to couple PT programs with highly enlightened enforcement of sanctions. In a sense, HCFA, "the ball is in your court!"
